Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2023 Earnings Conference Call August 8, 2023 4:30 AM ET

Company Participants

Tram Bui - VP, IR and Corporate Communications

Helen Torley - President and CEO

Nicole LaBrosse - CFO

Conference Call Participants

Mohit Bansal - Wells Fargo

Michael DiFiore - Evercore ISI

David Risinger - Leerink Partners

Jason Butler - JMP Securities

Mitchell Kapoor - H.C. Wainwright

Mack Chandler - Jefferies

Caroline Palomeque - Berenberg Capital Markets

Operator

Good afternoon, my name is Chris and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Halozyme Second Quarter 2023 Financial and Operating Results Conference Call. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] Please note this event is being recorded.

I'll now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations and Corporate Communications. Please go ahead.

Tram Bui

Thank you, operator. Good afternoon and welcome to our second quarter 2023 financial and operating results conference call. In addition to the press release issued today after the market close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.

Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer who will provide an update on our business and Nicole LaBrosse, our Chief Financial Officer will review our financial results for the second quarter 2023.

On today's call, we will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.

I will now turn the call over to Dr. Helen Torley.

Helen Torley

Thank you, Tram. Good afternoon, everyone. I will begin on Slide three. We're very pleased with our second quarter 2023 results where we delivered strong year-over-year top line and bottom line growth. With our partners we annex multiple milestone bearing Valley increasing events for the next wave of subcutaneous products that we project will deliver meaningful royalty revenues of Wave 3 products, most notably argenx's VYVGART Hytrulo that is coformulated with ENHANZE received FDA approval for generalized Myasthenia Gravis in June, making this the sixth approved product utilizing ENHANZE.